Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.61 |
| ▸ | MME | P08473 | 9/20 | 0.61 |
| ▸ | CPA1 | P15085 | 2/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.59 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21828686 | 1.00 | ACE (0.61) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL9822750 | 1.00 | ACE (0.61) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30123042 | 0.97 | MME (0.58) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL29666764 | 0.95 | ACE (0.56) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30414144 | 0.94 | MME (0.59) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30417812 | 0.94 | MME (0.59) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30123357 | 0.94 | ACE (0.55) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL29407166 | 0.93 | ACE (0.54) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30839478 | 0.92 | ACE (0.53) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL31613781 | 0.91 | NAALAD2 (0.62) | ACEMMECPA1ACE2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | claimed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | claimed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | claimed |
| US-20230374112-A1 | Bioactive Collagen Peptides, Method Of Production Thereof, And Use Thereof | BDC CAPITAL INC. (CA) | 2023-11-23 | — | — | US | claimed |
| CN-116406295-A | Anti-interleukin 36 receptor (IL-36R) therapy against ichthyosis | 安奈普泰斯生物有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-11680082-B2 | Conjugates of montelukast and peptides | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-06-20 | — | — | US | claimed |
| WO-2022067445-A1 | BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF | CORPORATION GENACOL CANADA INC. (CA) | 2022-04-07 | — | — | WO | claimed |
| JP-2121928-A | — | — | None | — | — | JP | disclosed |
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| US-20260027203-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ALETA BIOTHERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2025262265-A1 | CHIMERIC MOLECULES COMPRISING AN ANTI-FIBRIN ANTIBODY AND AN ANTITHROMBOTIC MOLECULE | ETABLISSEMENT FRANCAIS DU SANG (FR) | 2025-12-26 | — | — | WO | disclosed |
| CN-120081896-A | Functional peptide and seal penis peptide with yang strengthening effect, and preparation method and application thereof | 中国食品发酵工业研究院有限公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| WO-2022067445-A1 | BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF | CORPORATION GENACOL CANADA INC. (CA) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022025204-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | エポメッド株式会社 | 2022-02-03 | — | — | WO | disclosed |
| WO-2020071258-A1 | PROTEIN GLYCATION SUPPRESSANT | 味の素株式会社 | 2020-04-09 | — | — | WO | disclosed |
| US-5036052-A | Containing a dipeptide of tryptophan and alanine or lecine and no stabilizer; discoloration inhibition | MORISHITA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
| JP-H02121928-A | NUTRITIVE INFUSION SOLUTION COMPOSITION CONTAINING DIPEPTIDE OF L-TYROSINE | MORISHITA PHARMACEUT CO LTD | 1990-05-09 | — | — | JP | disclosed |
| EP-0347890-A1 | Amino acid nutrient compositions | Roussel Morishita Co., Ltd. (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027203-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | CD44, BCR, BAG6 | ACE 3896/4885MME 1299/4885CPA1 202/4885 |
| US-11680082-B2 | Conjugates of montelukast and peptides | IL33, HRH4, CYSLTR2 | ACE 2347/4885MME 3480/4885CPA1 1079/4885 |
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | VIP, ANPEP, RNPEP | ACE 132/4885MME 112/4885CPA1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.